EP1367994A2 - Comprimes a dissolution rapide d'inhibiteurs de l'enzyme cyclooxygenase-2 - Google Patents

Comprimes a dissolution rapide d'inhibiteurs de l'enzyme cyclooxygenase-2

Info

Publication number
EP1367994A2
EP1367994A2 EP02702595A EP02702595A EP1367994A2 EP 1367994 A2 EP1367994 A2 EP 1367994A2 EP 02702595 A EP02702595 A EP 02702595A EP 02702595 A EP02702595 A EP 02702595A EP 1367994 A2 EP1367994 A2 EP 1367994A2
Authority
EP
European Patent Office
Prior art keywords
tablet according
cox
group
inhibitor
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02702595A
Other languages
German (de)
English (en)
Inventor
Deepak Murpani
Vinod Kumar Arora
Rajiv Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1367994A2 publication Critical patent/EP1367994A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • the present invention relates to fast dissolving tablets for oral administration comprising a therapeutically effective amount of drug (s) that acts selectively as a cyclooxygenase-2 (COX-2) enzyme inhibitor, which disintegrate quickly in mouth.
  • drug s
  • COX-2 cyclooxygenase-2
  • Nonsteroidal anti-inflammatory drugs exert anti-inflammatory and analgesic effects through the inhibition of prostaglandin synthesis by blocking cyclooxygenase (COX) enzyme activity.
  • COX enzyme has two isoforms: COX-1 and COX-2.
  • COX-2 enzyme is inducible by inflammation, whereas COX-1 is present in most tissues as the house keeper enzyme. The inhibition of COX-1 is therefore undesirable whereas on the other hand inhibition of COX-2 enzyme accounts for the therapeutic benefits.
  • COX-2 inhibitors are the latest addition to the growing armamentarium of anti-inflammatory drugs. Much of the recent research has focussed upon efficacious methods for development of drug delivery of COX-2 enzyme inhibitors to treat inflammation associated maladies.
  • COX-2 inhibitors to selectively block formation of pro- inflammatory prostaglandins while sparing those that guard the gastrointestinal tract makes them an attractive choice for long term use, such as in rheumatoid arthritis or osteoarthritis.
  • Rheumatoid arthritis and osteoarthritis are old age diseases associated with joint pain, stiffness, inflammation or swelling. Many elderly persons have difficulty in taking conventional oral dosage forms like solutions, suspensions, tablets and capsules, because of hand tremors and dysphagia. Moreover, increase intake of water for swallowing conventional dosage forms results in frequent urination and nocturia.
  • Swallowing problems are also common in mentally ill, the developmentally disabled, and patients who are uncooperative, on reduced liquid-intake plans, or ⁇ are nauseated.
  • the tablets prepared by the present invention disintegrate and dissolve in the oral cavity in less than about 30 seconds without the need of water.
  • the fast dissolving tablet of COX-2 of the present invention process has pleasant mouth feel and there is no after taste or grittiness.
  • the fast dissolving tablets according to the present inventions comprises a therapeutically effective amount of COX-2 inhibitor, a filler, and optionally other pharmaceutical excipients.
  • the present invention provides a process for the preparation of fast dissolving tablets comprising a therapeutically effective amount of drug(s) that acts as a cyclooxygenase-2 (COX-2) inhibitor for oral administration.
  • the fast dissolving tablets of the present invention can either be produced by conventional methods like wet granulation, dry granulation and direct compression or by specialized techniques like tablet molding and freeze drying.
  • Direct compression is regarded as a relatively quick process where the powdered materials are compressed directly without changing the physical and chemical properties of the drug.
  • the advantages of direct compression include
  • the process comprises:
  • step (a) blending a therapeutically effective amount of COX-2 inhibitors with filler and optionally, other pharmaceutical acceptable excipients, for a time sufficient to form a homogeneous mixture. b) compressing the homogeneous mixture obtained in step (a) to form the fast dissolving tablet of COX-2 inhibitor.
  • COX-2 inhibitor as used herein to embrace compounds that specifically/selectively, or preferentially inhibits cyclooxygenase-2 over cyclooxygenase-1.
  • COX-2 enzyme inhibitors that are advantageously administered by the pharmaceutical compositions of this invention include "specific inhibitors” such as celecoxib, rofecoxib, parecoxib, valdecoxib, and the like or "preferential inhibitors” such as meloxicam, nimesulide, etodolac, nabumetone, and the like.
  • “Therapeutically effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • Fillers of the present invention can be selected from any such pharmaceutically acceptable excipient, which gives bulk to the COX-2 inhibitor composition and which is physically and chemically compatible with COX-2 inhibitor; preferably those fillers may be selected from alkali earth metal salts such as directly compressible dicalcium phosphate dihydrate, tricalcium phosphate, calcium sulfate, calcium carbonate, calcium hydroxide, aluminium hydroxide, magnesium silicate, aluminium magnesium hydroxide; carbohydrates such as directly compressible maltose, maltitol, sorbitol, mannitol, glucose, sucrose, xylitol, lactose, lactose monohydrate, erythritol, fructose, maltodextrins; celluloses such as microcrystalline cellulose, calcium carboxy methyl cellulose; starches such as pregelatinized starch, potato starch, maize starch; clays such as kaolin and polyethylene glycols (PEG) such as PEG 4000 ; or mixtures thereof
  • the effective amount of the fillers found useful in the present invention is in the range of about 10 to about 95 weight percent , preferably about 25 to about 85 weight percent, and most preferably about 80 weight ' percent of the COX-2 inhibitor compositions of this invention.
  • One of the preferred fillers is directly compressible mannitol.
  • the direct compression excipients are chosen such that they have good flow and compressible characteristics and prevent segregation of powders in the hopper and thereby help in direct compression.
  • the optional pharmaceutical excipients of this invention may be selected from the binders, disintegrants, lubricants, glidants, colouring agents, flavouring agents and sweeteners which are chemically and physically compatible with COX-2 enzyme inhibitors.
  • the direct compression method for preparing tablets requires a material that not only is free-flowing but also sufficiently cohesive to act as a binder.
  • microcrystalline cellulose such as microcrystalline cellulose, microcrystalline dextrose, mannitol, directly compressible dicalcium phosphate, amylose and polyvinylpyrrolidone have such properties.
  • Disintegrants preferred for the present invention may be selected from starches or modified starches such as sodium starch glycolate, corn starch, potato starch or pregelatinized starch; clays such as bentonite, montmorillonite or veegum; celluloses such as microcrystalline cellulose, hydroxypropyl cellulose or carboxymethyl cellulose; algins such as sodium alginate or alginic acid; cross- linked cellulose such as croscarmellose sodium; gums such as guar gum or xanthan gum; cross-linked polymers such as crospovidone; effervescent agent such as sodium bicarbonate and citric acid; or mixtures thereof.
  • starches or modified starches such as sodium starch glycolate, corn starch, potato starch or pregelatinized starch
  • clays such as bentonite, montmorillonite or veegum
  • celluloses such as microcrystalline cellulose, hydroxypropyl cellulose or carboxymethyl cellulose
  • algins such as sodium alginate or
  • the effective amount of a disintegrant found useful for the COX-2 inhibitor compositions of this invention is in the range of about 1.0 to about 10.0 weight percent, preferably about 1.5 to about 2.5 weight percent and most preferably about 2.0 weight percent of the COX-2 inhibitor compositions by this invention.
  • the preferred disintegrant is croscarmellose sodium.
  • the lubricants of the present invention may be selected from talc, magnesium stearate, calcium stearate, stearic acid, magnesium lauryl sulphate and hydrogenated vegetable oil. Soluble lubricants include sodium benzoate, a mixture of sodium benzoate and sodium acetate, sodium chloride, leucine, sodium stearyl fumarate and PEG 4000.
  • the effective amount of lubricant found useful in the present invention is in the range of about 0.25 to about 4 weight percent, preferably about 0.5 to about 2 weight percent, and most preferably 1.0 weight percent of the COX-2 inhibitor compositions of this invention.
  • the preferred lubricant is magnesium stearate.
  • the glidants of the present invention may be selected from colloidal silicon dioxide and talc.
  • the coloring agent of the present invention may be selected from any colorant used in pharmaceuticals which is approved and certified by the FDA.
  • the flavouring agent of the present invention include both natural and artificial flavours such as artificial vanilla, cinnamon, various fruit flavours, both individual and mixed; mints such as peppermint, menthol; essential oils such as thymol, eculyptol and methyl salicylate and the like.
  • the flavours are generally utilized in amounts that will vary depending upon the individual flavour, and may range in amounts of about 0.5% to about 3% by weight of the final composition weight.
  • the sweeteners for the present invention include both natural and artificial sweetners.
  • the sweetners may include, among others, water-soluble sweetening agents such as monosaccharides, disaccharides and polysaccharides such as xylose, ribose, glucose, mannose, galactose, fructose, dextrose, sucrose, maltose, partially hydrolyzed starch, or com syrup solids and sugar alcohols such as sorbitol, xylitol, mannitol and mixtures thereof; water- soluble artificial sweeteners such as the soluble saccharin salts, cyclamate salts, acesulfam-K and the like, and free acid form of saccharin and dipeptide based sweeteners.
  • the amount of sweetener will vary with the desired sweeteners selected for a particular tablet composition.
  • the process of the present invention comprises sieving of the COX-2 inhibitors, fillers, disintegrants, binders, glidants, colouring agents, flavouring agents and sweeteners, through a suitable sieve and admixing them to make a uniform blend.
  • the lubricant is also passed through the suitable sieve and mixed with the blend.
  • the blend is directly compressed using the suitable tooling.
  • the tablets made by the present inventive process disintegrate / dissolve in less than about 30 seconds preferably in about 25 seconds.
  • the process of this invention for preparing rapidly dissolving tablet may be used for any strength of COX-2 inhibitor tablets without deviating from this invention.
  • Rofecoxib, aspartame, mannitol, croscarmellose sodium, colloidal silicon dioxide and mixed fruit flavour are sifted through the sieve #44 BSS and admixed for about 15 minutes to make a uniform blend.
  • Magnesium stearate is passed through sieve #100 BSS and mixed with the blend of step 1 for sufficient time.
  • step 2 Uniform blend of step 2 is directly compressed using 9 mm, round biconcave tooling to make the tablets of about 3.8 ⁇ 0.1 mm thickness.
  • the mouth dissolving tablets prepared by the above composition and process had hardness in the range of 2.2 to about 4.0 Kp.
  • the disintegration time in water was less than 15 seconds, whereas the mouth dissolving time was less than 25 seconds.
  • the friability was about 0.4 % w/w.
  • the mouth dissolving rofecoxib tablets are tested in 1 % sodium lauryl sulphate (SLS) according to the procedure described in the United States Pharmacopoeia XXIII, Apparatus 1 @ 100 rpm and found to have the following release profile:
  • Example 1 The procedure of Example 1 was followed to prepare the tablets of above composition.
  • the rofecoxib mouth dissolving tablet of 50 mg strength had an average weight of 400 ⁇ 20 mg, thickness of 4.9 ⁇ 0.2 mm, hardness of 4.5-5.0 Kp, disintegration time of less than 20 seconds, mouth dissolving time of about 25 seconds, friability of about 0.44% w/w and dissolution upto 86% in 45 minutes.
  • Example 1 The procedure of Example 1 was followed to prepare the above tablets.
  • the nimesulide mouth dissolving tablet of 100 mg strength had an average weight of 450 ⁇ 22.5 mg, thickness of 5.7+0.2 mm, hardness of 2-5 Kp, disintegration time of less than 20 seconds, mouth dissolving time of about 25 seconds and friability of about 0.9% w/w. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des comprimés à dissolution rapide destinés à l'administration orale comprenant une quantité thérapeutiquement efficace d'un ou plusieurs médicaments agissant comme inhibiteurs de l'enzyme cyclooxygénase-2 (COX-2), lesquels comprimés se désintègrent rapidement en bouche. Les comprimés de l'invention sont particulièrement adaptés aux patients qui éprouvent des difficultés pour avaler.
EP02702595A 2001-02-27 2002-02-27 Comprimes a dissolution rapide d'inhibiteurs de l'enzyme cyclooxygenase-2 Withdrawn EP1367994A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INDE00000189 2001-02-27
IN189DE2001 2001-02-27
PCT/IB2002/000587 WO2002067894A2 (fr) 2001-02-27 2002-02-27 Comprimes a dissolution rapide d'inhibiteurs de l'enzyme cyclooxygenase-2

Publications (1)

Publication Number Publication Date
EP1367994A2 true EP1367994A2 (fr) 2003-12-10

Family

ID=11097035

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02702595A Withdrawn EP1367994A2 (fr) 2001-02-27 2002-02-27 Comprimes a dissolution rapide d'inhibiteurs de l'enzyme cyclooxygenase-2

Country Status (9)

Country Link
EP (1) EP1367994A2 (fr)
AU (1) AU2002236120A1 (fr)
CZ (1) CZ20032568A3 (fr)
HU (1) HUP0400098A2 (fr)
IS (1) IS6932A (fr)
OA (1) OA12686A (fr)
PL (1) PL363771A1 (fr)
SK (1) SK11802003A3 (fr)
WO (1) WO2002067894A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
GB0724707D0 (en) * 2007-12-19 2008-01-30 Burke Michael H A process for the preparation of an orally administered unit dose tablet
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN108653225B (zh) * 2018-08-15 2021-01-08 湖北舒邦药业有限公司 一种尼美舒利制剂及其制备方法
CN112569178B (zh) * 2020-12-29 2022-09-09 南京百泽医药科技有限公司 一种帕瑞昔布药物组合物制备方法及用作舌下制剂的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA964928B (en) * 1995-06-13 1997-12-10 American Home Prod Oral formulations of S(+)-etodolac.
EP0945134A1 (fr) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Nouvelles formes galeniques du meloxicam pour administration par voie orale
WO2001085134A1 (fr) * 2000-05-12 2001-11-15 Emcure Pharmaceuticals Ltd Compositions pharmaceutiques solides et procede de production de comprimes se dissolvant dans la bouche

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02067894A3 *

Also Published As

Publication number Publication date
HUP0400098A2 (hu) 2004-04-28
OA12686A (en) 2006-06-21
AU2002236120A1 (en) 2002-09-12
PL363771A1 (en) 2004-11-29
IS6932A (is) 2003-08-27
WO2002067894A2 (fr) 2002-09-06
CZ20032568A3 (cs) 2004-04-14
WO2002067894A3 (fr) 2002-12-19
SK11802003A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
US20030161875A1 (en) Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
JP5537943B2 (ja) 速崩壊性固形製剤
ES2347968T3 (es) Preparacion solida que se disgrega rapidamente.
JP4965130B2 (ja) 乾式直打速崩壊性錠剤
WO2007074472A2 (fr) Composition pharmaceutique se dissolvant dans la bouche et son procede de preparation
JP2004521955A (ja) 新規置換ベンズイミダゾール製剤およびその使用方法
JP2006501233A (ja) 速溶解性かつ味覚を掩蔽したシルデナフィル配合経口投薬形態
CN110475544B (zh) 包含氨基甲酸酯化合物的口腔崩解片
WO2008079342A2 (fr) Comprimés à désintégration par voie orale: composition utilisée et méthode de fabrication orale
JP2008285434A (ja) 口腔内速崩壊錠
JP2001513801A (ja) パラセタモールを含む嚥下錠剤
JP2000095675A (ja) 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物
JP2004175796A (ja) 排尿障害治療用口腔内崩壊製剤
WO2009150665A1 (fr) Compositions pharmaceutiques à désintégration orale d’escitalopram et de sels de celui-ci
JP4812626B2 (ja) 口腔内溶解用固形製剤
NO329896B1 (no) Farmasoytisk sammensetning og anvendelse derav
JP4090997B2 (ja) ペリンドプリルの口内分散性薬剤組成物
WO2002067894A2 (fr) Comprimes a dissolution rapide d'inhibiteurs de l'enzyme cyclooxygenase-2
JP4173670B2 (ja) 口腔内崩壊製剤
AU2003253198A1 (en) Bicifadine formulation
JP4814636B2 (ja) ビグアナイド系薬物の内服製剤
JP2002193839A (ja) ココア製剤
WO2005077341A1 (fr) Compositions pharmaceutiques a desintegration orale d'ondansetron
AU2011379627B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
JP2005060309A (ja) 不快な味を低減した口腔内崩壊錠剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030929

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20050318

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060404